Alemtuzumab and rheumatoid arthritis - an immunisation study
Phase of Trial: Phase IV
Latest Information Update: 14 May 2019
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- 12 May 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 04 Mar 2015 Accrual to date is 55% according to United Kingdom Clinical Research Network.